| scholarly article | Q13442814 |
| P50 | author | Swaminathan Padmanabhan | Q54580338 |
| P2093 | author name string | James E Bradner | |
| Bhavin Shah | |||
| Jun Qi | |||
| Ming Zhan | |||
| Sunil Sharma | |||
| Kapil N Bhalla | |||
| Warren Fiskus | |||
| Jianting Sheng | |||
| Bryce P Portier | |||
| Melissa Rodriguez | |||
| Leasha J Schaub | |||
| Karissa Peth | |||
| Santhana G T Devaraj | |||
| John A Valenta | |||
| P433 | issue | 5 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 1142-1154 | |
| P577 | publication date | 2014-01-16 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells | |
| P478 | volume | 13 |
| Q39207675 | A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers |
| Q98289634 | Anti-Diabetic Atherosclerosis by Inhibiting High Glucose-Induced Vascular Smooth Muscle Cell Proliferation via Pin1/BRD4 Pathway |
| Q38799987 | BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells |
| Q90299058 | BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition |
| Q28066765 | BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects |
| Q38609772 | BET inhibitors: a novel epigenetic approach |
| Q34289202 | BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. |
| Q37693266 | BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells |
| Q61807137 | BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes |
| Q33730555 | BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma |
| Q92868816 | BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo |
| Q38537879 | Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. |
| Q38824596 | Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration. |
| Q90160312 | Clinical developments in epigenetic-directed therapies in acute myeloid leukemia |
| Q47212126 | Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. |
| Q36356381 | Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling |
| Q38900285 | Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function |
| Q36523796 | Digging deep into "dirty" drugs - modulation of the methylation machinery |
| Q89184502 | Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2 |
| Q45141257 | Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma |
| Q57057393 | Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma |
| Q38837858 | Epigenetic Determinants of Cancer |
| Q33275721 | Epigenetic deregulations in chordoma |
| Q26765402 | Epigenetic regulators and their impact on therapy in acute myeloid leukemia |
| Q26865149 | Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia |
| Q28076548 | Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? |
| Q90440161 | Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma |
| Q57493686 | Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapies |
| Q35740207 | H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription. |
| Q39559758 | HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. |
| Q88984691 | Hematopoietic stem cells made BETter by inhibition |
| Q36962647 | High level of BRD4 promotes non-small cell lung cancer progression |
| Q41664067 | Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises |
| Q38796064 | Histone Modifications and Cancer |
| Q38866094 | Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia |
| Q36545233 | Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells |
| Q64061318 | Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy |
| Q42032794 | Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. |
| Q38679327 | Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). |
| Q26859355 | KATs in cancer: functions and therapies |
| Q89756562 | Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors |
| Q37643136 | Molecular therapeutic approaches for pediatric acute myeloid leukemia |
| Q47740361 | Natural Agents-Mediated Targeting of Histone Deacetylases. |
| Q41190385 | Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q35685058 | Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells |
| Q59794233 | Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma |
| Q48316021 | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling |
| Q35750491 | Rational Combinations of Targeted Agents in AML |
| Q64096005 | Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity |
| Q26781203 | Regulation of Bim in Health and Disease |
| Q33842529 | Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia |
| Q36723302 | Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins |
| Q38752928 | SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. |
| Q36242646 | Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia |
| Q35988744 | Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer |
| Q91518791 | Stem cell fate in cancer growth, progression and therapy resistance |
| Q91933011 | Super-enhancers: critical roles and therapeutic targets in hematologic malignancies |
| Q60907880 | Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells |
| Q36091288 | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib |
| Q91750656 | Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors |
| Q47385983 | Targeting bromodomain and extraterminal proteins in breast cancer |
| Q28238635 | Targeting bromodomains: epigenetic readers of lysine acetylation |
| Q38821103 | Targeting the cancer epigenome for therapy |
| Q36169695 | The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs |
| Q38260084 | The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition |
| Q55246679 | The Bromodomain Inhibitor JQ1 Enhances the Responses to All-trans Retinoic Acid in HL-60 and MV4-11 Leukemia Cells. |
| Q41330428 | The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia |
| Q35766387 | Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. |
| Q92541724 | Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia |
| Q39175665 | Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
| Q26766152 | Update on rational targeted therapy in AML |
| Q38668641 | What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy? |
Search more.